Life Sciences & Biotechnology
Title : | A randomised controlled trial of single-dose oral Ivermectin in patients with COVID-19 infection |
Area of research : | COVID-19 Research, Life Sciences & Biotechnology |
Focus area : | COVID-19 Therapeutics |
Principal Investigator : | Dr Anant Mohan, Professor, All India Institute of Medical Sciences (AIIMS), New Delhi |
Timeline Start Year : | 2020 |
Timeline End Year : | 2020 |
Contact info : | anantmohan@yahoo.com |
Details
Executive Summary : | This project aims to evaluate the efficacy of (1) single-dose Ivermectin in reducing viral load in COVID-19 patients, (2) Ivermectin in time with clinical improvement, the percentage of patients progressing to severe disease, and frequency of adverse events in both arms. |
Outcome/Output: | A single oral administration of Ivermectin at two dosage strength (24 mg and 12 mg) to patients with mild and moderate COVID-19 in reducing SARS-COV-2 viral load was tested. There was no difference in the decline of viral load on day five between the three arms. No serious adverse events were encountered in patients with mild and moderate COVID-19. |
Organizations involved